Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rakovina (RKV) is partnering with St. Baldrick’s Foundation to develop treatments for childhood bone cancer
  • It was selected to join a three-year C$1,297,000 research program funded by St. Baldrick’s Martha’s BEST Grant for All
  • The grant focuses on treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults
  • Dr. Mads Daugaard, Co-founder, President, and CSO sat down with Dave Jackson to discuss Rakovina’s partnership with St. Baldrick’s Foundation
  • The company recently presented preclinical data demonstrating the potential of its kt-3000 series drug candidates against Ewing sarcoma
  • Rakovina Therapeutics develops new cancer treatments based on novel DNA-damage response technologies
  • Rakovina (RKV) is unchanged trading at $0.22 per share

Rakovina (RKV) is partnering with St. Baldrick’s Foundation to develop treatments for childhood bone cancer.

The company was selected to join a three-year C$1,297,000 research program funded by St. Baldrick’s Martha’s BEST Grant for All, which focuses on treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

It will supply test compounds and support the project with technical personnel, while funding from the St. Baldrick’s Foundation will support pre-clinical IND-enabling research at the University of British Columbia over the next 12 months.

Rakovina recently presented preclinical data at peer-reviewed scientific meetings demonstrating the potential of its kt-3000 series drug candidates against treatment-resistant cancer cell lines, including Ewing sarcoma.

Dr. Mads Daugaard, Co-founder, President, and CSO sat down with Dave Jackson to discuss Rakovina’s partnership with St. Baldrick’s Foundation.

“Our data demonstrate that kt-3000 series compounds are equal or more effective against Ewing sarcoma cells in vitro in comparison to FDA-approved PARP-inhibitors, which are used as benchmarks for activity.

Currently, there are no FDA-approved treatments for relapsed Ewing sarcoma, which is largely resistant to conventional therapies as well as immunotherapy; new treatment strategies are sorely needed.”

Jeffrey Bacha, Rakovina’s Executive Chairman, added,

“Rakovina Therapeutics is pleased to be an industry partner in the St. Baldrick’s Foundation mission to support the most promising research to find cures for childhood cancers and give survivors long and healthy lives. We will seek to rapidly advance drug candidates into the clinical arena if pre-clinical IND-enabling work permits.”

Rakovina Therapeutics develops new cancer treatments based on novel DNA-damage response technologies.

Rakovina (RKV) is unchanged trading at $0.22 per share as of 10:09 am ET.

More From The Market Herald
The Market Herald Video

" LUXXFOLIO Holdings (CSE:LUXX) provides operational update

LUXXFOLIO Holdings’ (LUXX) November updates includes record mining revenues of approximately $1.8 million and monthly rewards of 23.5 Bitcoin.
LexaGene - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) closes multiple MiQLab sales

LexaGene (LXG) has received purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
The Market Herald Video

" FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.